Literature DB >> 2190866

Antibody to selected strains of Saccharomyces cerevisiae (baker's and brewer's yeast) and Candida albicans in Crohn's disease.

H McKenzie1, J Main, C R Pennington, D Parratt.   

Abstract

IgG serum antibody was measured by ELISA in patients with Crohn's disease (15), ulcerative colitis (15), and in normal controls (15) to 12 strains of Saccharomyces cerevisiae (baker's and brewer's yeast) and to the two major serotypes of the commensal yeast Candida albicans. Antibody to 11 of the 12 strains of S cerevisiae was raised in patients with Crohn's disease but not in patients with ulcerative colitis when compared with controls (p less than 0.001). The pattern of antibody response to these 11 strains was variable, however, suggesting the likelihood of antigenic heterogeneity within the species. Antibody to C albicans was not significantly different in patient and control groups. The specificity of this unusual antibody response in Crohn's disease for S cerevisiae suggests that it is not simply the result of a generalised increase in intestinal permeability. Furthermore, because brewing and baking strains detected the response, the relevant antigen(s) are presumably common in the diet. Hypersensitivity to dietary antigens may be involved in the pathogenesis of Crohn's disease, and the role of S cerevisiae requires further investigation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2190866      PMCID: PMC1378569          DOI: 10.1136/gut.31.5.536

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  9 in total

Review 1.  Mycobacteria and Crohn's disease.

Authors:  S J Hampson; J J McFadden; J Hermon-Taylor
Journal:  Gut       Date:  1988-08       Impact factor: 23.059

2.  Serum antibodies to mycobacterial antigens in active Crohn's disease.

Authors:  K Kobayashi; W R Brown; P J Brennan; M J Blaser
Journal:  Gastroenterology       Date:  1988-06       Impact factor: 22.682

Review 3.  Mycobacterial antigens: a review of their isolation, chemistry, and immunological properties.

Authors:  T M Daniel; B W Janicki
Journal:  Microbiol Rev       Date:  1978-03

4.  Circulating antibodies to bovine albumin in ulcerative colitis and Crohn's disease. Characterization of the antibody response.

Authors:  K R Falchuk; K J Isselbacher
Journal:  Gastroenterology       Date:  1976-01       Impact factor: 22.682

5.  Crohn's disease: maintenance of remission by diet.

Authors:  V A Jones; R J Dickinson; E Workman; A J Wilson; A H Freeman; J O Hunter
Journal:  Lancet       Date:  1985-07-27       Impact factor: 79.321

6.  Isotypic analysis of antibody response to a food antigen in inflammatory bowel disease.

Authors:  R Paganelli; F Pallone; S Montano; S Le Moli; P M Matricardi; S Fais; P Paoluzi; R D'Amelio; F Aiuti
Journal:  Int Arch Allergy Appl Immunol       Date:  1985

7.  Serum antibodies to cow's milk proteins in ulcerative colitis and Crohn's disease.

Authors:  P Knoflach; B H Park; R Cunningham; M M Weiser; B Albini
Journal:  Gastroenterology       Date:  1987-02       Impact factor: 22.682

8.  Antibodies to maize in patients with Crohn's disease, ulcerative colitis and coeliac disease.

Authors:  I W Davidson; R S Lloyd; P J Whorwell; R Wright
Journal:  Clin Exp Immunol       Date:  1979-01       Impact factor: 4.330

9.  Antibody to Saccharomyces cerevisiae (bakers' yeast) in Crohn's disease.

Authors:  J Main; H McKenzie; G R Yeaman; M A Kerr; D Robson; C R Pennington; D Parratt
Journal:  BMJ       Date:  1988-10-29
  9 in total
  49 in total

1.  Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn's disease.

Authors:  C L Sutton; H Yang; Z Li; J I Rotter; S R Targan; J Braun
Journal:  Gut       Date:  2000-01       Impact factor: 23.059

Review 2.  Diagnostic methodologies: serology, endoscopy, and radiology.

Authors:  T Dassopoulos
Journal:  Curr Gastroenterol Rep       Date:  2001-12

3.  Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics.

Authors:  E A Vasiliauskas; L Y Kam; L C Karp; J Gaiennie; H Yang; S R Targan
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

Review 4.  Recent advances in the diagnosis and classification of inflammatory bowel disease.

Authors:  Eric Vasiliauskas
Journal:  Curr Gastroenterol Rep       Date:  2003-12

5.  Antibodies to Saccharomyces cerevisiae in patients with Crohn's disease and their possible pathogenic importance.

Authors:  M H Giaffer; A Clark; C D Holdsworth
Journal:  Gut       Date:  1992-08       Impact factor: 23.059

6.  Anti-saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy.

Authors:  I E A Hoffman; P Demetter; M Peeters; M De Vos; H Mielants; E M Veys; F De Keyser
Journal:  Ann Rheum Dis       Date:  2003-05       Impact factor: 19.103

7.  Immunoglobulin A (IgA) and IgG serum antibodies to mycobacterial antigens in Crohn's disease patients and their relatives.

Authors:  L G Wayne; D Hollander; B Anderson; H A Sramek; C M Vadheim; J I Rotter
Journal:  J Clin Microbiol       Date:  1992-08       Impact factor: 5.948

Review 8.  Immunopathogenesis of IBD: current state of the art.

Authors:  Heitor S P de Souza; Claudio Fiocchi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-12-02       Impact factor: 46.802

9.  CARD15 polymorphisms are associated with anti-Saccharomyces cerevisiae antibodies in caucasian Crohn's disease patients.

Authors:  B Vander Cruyssen; H Peeters; I E A Hoffman; D Laukens; P Coucke; D Marichal; C Cuvelier; E Remaut; E M Veys; H Mielants; M De Vos; F De Keyser
Journal:  Clin Exp Immunol       Date:  2005-05       Impact factor: 4.330

10.  Antibody (IgG, IgA, and IgM) to baker's yeast (Saccharomyces cerevisiae), yeast mannan, gliadin, ovalbumin and betalactoglobulin in monozygotic twins with inflammatory bowel disease.

Authors:  E Lindberg; K E Magnusson; C Tysk; G Järnerot
Journal:  Gut       Date:  1992-07       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.